Sino Medical Sciences Technology Inc.

SINOMED (Sino Medical Sciences Technology Inc.) is a leading international medical device company headquartered in Tianjin, China, specializing in high-end interventional devices for cardiovascular, cerebrovascular, and structural heart diseases. Founded in 2007, the company has established itself as a market leader in coronary stent technology with a publicly traded presence on the Shanghai STAR market (Stock Code: 688108.SH). SINOMED's product portfolio includes drug-eluting stents, intracranial drug-eluting stents, and transapical mitral valve replacement systems, with devices deployed in over 2.85 million procedures across more than 2,000 hospitals globally. The company maintains a strong commitment to innovation, investing approximately 30% of revenue in research and development and holding over 200 global patents. With subsidiaries in the United States, Japan, and France, SINOMED operates a 720-person workforce and conducts extensive clinical trials to validate device safety and efficacy. The organization focuses on minimally invasive treatment solutions that improve patient outcomes and quality of life across cardiovascular and structural heart disease markets.